Nanocarry is developing a new class of brain therapeutics, which combines biological approaches with nanoparticles to allow biologics to cross the Blood Brain Barrier, creating first-in-class therapeutics for neuro-oncology indications and CNS diseases.
Nanocarry is developing an innovative delivery technology platform pioneered over the past decade in the Nano-Bioengineering lab of Prof. Rachela Popovtzer at Bar Ilan University, Israel. With pre-seed financing from NfX, Nanocarry’s nano-chemistry and biology labs are working synergistically to develop first-in-class product candidates, while scaling and optimizing the manufacturing process of its bioengineered nanoparticles.
